Travere Therapeutics, 2.5% 15sep2025, USD (Conv.) (FIGI BBG00LWSMG97, WKN A2RRM0)
国内債券, 転換社債, トレース適格, Senior Unsecured
国内債券, 転換社債, トレース適格, Senior Unsecured
|
Retrophin Inc. (Retrophin), formerly Desert Gateway, Inc., is a biotechnology company. The Company focused on discovering and developing treatments for rare and life-threatening diseases. The Company is developing treatments for Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated ...
Retrophin Inc. (Retrophin), formerly Desert Gateway, Inc., is a biotechnology company. The Company focused on discovering and developing treatments for rare and life-threatening diseases. The Company is developing treatments for Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases.
|
|
|
|
|
|
|
|
|
最も包括的なデータベースを探索
1 000 000
債券
80 234
株
167 970
ETF&投資信託
70 000
インデックス
最も効率的な方法でポートフォリオを追跡
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |